Insmed (INSM) EBITDA (2010 - 2026)

Insmed has reported EBITDA for 17 years, with the latest figure at -$1.5 million in Q2 2026.

• On a quarterly basis, EBITDA rose 99.51% year-over-year to -$1.5 million in Q2 2026; TTM through Jun 2026 was -$840.6 million, a 16.34% increase from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 41.96% from the prior year.
• EBITDA was -$1.5 million for Q2 2026 at Insmed, up from -$153.3 million in the prior quarter.
• The five-year high for EBITDA was -$1.5 million in Q2 2026, with the low at -$366.0 million in Q3 2025.
• Average EBITDA over 5 years is -$191.5 million, with a median of -$165.8 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: EBITDA sank 166.69% in 2023, then surged 99.51% in 2026.
• Over 5 years, EBITDA stood at -$151.5 million in 2022, then dropped by 17.69% to -$178.3 million in 2023, then dropped by 29.25% to -$230.4 million in 2024, then tumbled by 38.77% to -$319.7 million in 2025, then soared by 99.52% to -$1.5 million in 2026.
• The last three EBITDA figures came in at -$1.5 million (Q2 2026), -$153.3 million (Q1 2026), and -$319.7 million (Q4 2025), per Business Quant data.